Scant evidence for Mesoblast's stem cell candidate in treating pain, say experts

25 January 2020

In the search for non-opioid options to treat pain, Australian biotech Mesoblast (ASX: MSB) has turned to a stem cell approach, which is currently in late-stage development for chronic low back pain. However, interviewed experts say its potential for Phase III success is uncertain due to scant human evidence with this stem cell product for treating pain.

Even if it reaches the market, the therapy would face various access restrictions, according to reporting from Shuan Sim, pharma writer for the investigative news team at analytics firm GlobalData.

Mr Sim comments: “While Mesoblast’s MPC-06-ID is projected to be a multi-billion-dollar asset, experts whom I spoke to do not believe the therapy would reach blockbuster status easily.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK